IDEXX Laboratories, Inc. — Form 10-Q Summary
Business context and reporting period
Unaudited results for the three and nine months ended September 30, 2010, compared with the corresponding 2009 periods. IDEXX operates through Companion Animal Group (CAG), Water, Livestock and Poultry Diagnostics (LPD), and smaller Dairy and OPTI Medical businesses.
Key financial metrics
| Metric | Q3 2010 | Q3 2009 | 9M 2010 | 9M 2009 |
|---|---|---|---|---|
| Total revenue | $269.6 million | $259.1 million | $819.6 million | $761.3 million |
| Gross profit | $142.2 million | $130.5 million | $433.9 million | $393.4 million |
| Gross margin | 52.7% | 50.4% | 52.9% | 51.7% |
| Operating income | $49.8 million | $44.2 million | $153.1 million | $131.8 million |
| Operating margin | 18.5% | 17.1% | 18.7% | 17.3% |
| Net income attributable to IDEXX | $34.7 million | $31.5 million | $104.9 million | $91.3 million |
| Diluted EPS | $0.59 | $0.52 | $1.76 | $1.50 |
Revenue increased 4.1% in Q3 and 7.7% for the first nine months. Organic revenue growth, excluding currency and acquisition or divestiture effects, was 4.9% in Q3 and 6.4% for the nine months. CAG revenue was $222.9 million in Q3 and $676.6 million for the nine months.
- Nine-month operating cash flow was $130.0 million, up from $115.5 million.
- Capital expenditures were $28.6 million; management expected approximately $45 million for full-year 2010.
- Cash and cash equivalents were $133.5 million at September 30, 2010, versus $106.7 million at December 31, 2009.
- Working capital was $159.0 million at September 30, 2010, versus $120.0 million at year-end 2009.
- Credit Facility borrowings were $125.9 million, with $73.1 million of remaining availability under the $200 million facility. The company was in compliance with its debt covenants.
- Other long-term and current debt totaled approximately $4.5 million, excluding the Credit Facility.
- Share repurchases used $117.2 million during the first nine months, including 2.1 million shares at an average cost of $56.25 per share.
Material changes versus the prior comparable period
- Gross and operating margins improved, primarily from lower manufacturing and service costs, manufacturing scale benefits, and lower depreciation on instruments placed at customer sites.
- CAG instruments and consumables revenue increased 7.7% for the nine months, while laboratory diagnostic and consulting services increased 11.4% and practice information systems and digital radiography increased 19.5%.
- Rapid assay revenue declined 1.3% for the nine months, driven by lower pricing from customer programs and lower U.S. practice-level sales.
- LPD revenue increased 5.1% for the nine months, helped by German government testing tenders; Water revenue increased 4.8%.
- Q3 revenue was negatively affected by approximately $3.2 million from foreign exchange, while nine-month revenue benefited by approximately $5.7 million from currency movements.
- Interest expense increased to $1.7 million for the nine months from $1.5 million. Interest-rate swaps effectively fixed the rate on $80 million of variable-rate debt at 2% plus the applicable Credit Spread through March 2012.
- The effective tax rate increased to 30.8% from 30.1% for the nine months, primarily because federal research and development tax incentives available in 2009 expired.
- Inventory increased to $131.6 million from $110.4 million at year-end 2009, primarily reflecting timing of inventory receipts. Finished goods increased to $88.8 million from $64.2 million.
Guidance, outlook, commentary, risks and unusual items
The filing does not provide clear formal full-year revenue or earnings guidance. Management stated that cash on hand, operating cash flow and available borrowings should fund operations, capital requirements and strategic growth for at least the next twelve months and over the longer term as currently conducted.
- Management continued to observe essentially flat veterinary patient visits and expected weak economic conditions to negatively affect growth, pricing, instrument purchases and testing volumes.
- Distributor inventory movements materially affected reported CAG revenue, particularly rapid assay products. Distributor purchasing may not reflect underlying end-user demand.
- Management expects interest expense to remain higher during the remainder of 2010 because of the fixed-rate swaps.
- IDEXX received an FTC investigation letter in January 2010 and a subpoena in April 2010 concerning possible unfair competition involving companion-animal pricing and marketing practices. The company intends to cooperate and believes its practices comply with applicable law.
- A $1.0 million sales milestone from previously divested pharmaceutical products reduced general and administrative expense in Q3. Up to $8.5 million of additional sales-based milestone payments remained possible.
- Key risks include economic weakness, foreign exchange exposure, regulatory approvals and enforcement, competition, distributor concentration and purchasing patterns, reliance on sole or single-source suppliers, biologic manufacturing complexity, patent risks, facility or system interruptions, changing testing patterns, and tax uncertainties.
- Approximately 25% of nine-month revenue was attributable to international customers, and approximately 24% of Q3 revenue came from products manufactured in the U.S. and sold internationally in local currencies.
Important facts for investors to verify
- Underlying end-user demand versus distributor inventory effects, especially for rapid assays and instrument consumables.
- Sustainability of CAG laboratory-services growth and the contribution from ProCyte Dx, Catalyst Dx and digital radiography products.
- Resolution and potential financial or operational consequences of the FTC investigation.
- Liquidity after $117.2 million of share repurchases, current Credit Facility borrowings, covenant headroom and the concentration of cash outside the United States.
- Inventory growth, working-capital requirements and the timing of approximately $45 million of planned 2010 capital expenditures.
- Impact of foreign exchange, expiration of tax incentives, fixed-rate swaps and competitive pricing on future margins.
- Dependence on regulatory approvals, government-funded testing programs, sole-source suppliers and key manufacturing facilities.